Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07FQL
|
|||
| Former ID |
DNCL001887
|
|||
| Drug Name |
Diannexin
|
|||
| Indication | Myocardial reperfusion injury [ICD-11: NB31] | Phase 2 | [1] | |
| Company |
Altavita Pharmaceuticals; Astellas Pharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Annexin A5 (ANXA5) | Target Info | Modulator | [2] |
| WikiPathways | Prostaglandin Synthesis and Regulation | |||
| Apoptosis-related network due to altered Notch3 in ovarian cancer | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00615966) Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients. U.S. National Institutes of Health. | |||
| REF 2 | Expression and purification of recombinant human annexin V in Escherichia coli. Prep Biochem Biotechnol. 2000 Nov;30(4):305-12. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.